Movianto UK Doubles its Cold Storage Capacity and Dedicated Storage for Narcotics

Movianto UK Doubles its Cold Storage Capacity and Dedicated Storage for Narcotics

BEDFORD, England, June 22, 2011 /PRNewswire/ --

Movianto UK, the healthcare logistics specialists, has further underlined its commitment to the pharmaceutical and healthcare industry in the UK with substantial investment made in the expansion of their cold chain and narcotics facilities.

The company, based in Bedford with 8 depots across the UK, has completed an expansion of their facilities for cold storage in time for the procurement period as stocking starts in the late summer time. Error-free services in cold storage are an imperative as sensitive drugs need to be stored between 2°C - 8 °C. This temperature range cannot be interrupted at any time otherwise the drugs may be rendered useless, worthless and, in the worst case, dangerous. Movianto has not only doubled its cold storage capacity to 4,500 pallet spaces but also installed a temperature controlled loading, unloading and packing facility. This investment when combined with Movianto's unique ability to deliver everywhere in the UK every day with their own temperature controlled fleet, re-affirms Movianto as the market leader within the UK.

But it is not only cold chain products that need careful expert handling. The storage and transport of narcotics must be maintained in high security environments. The investment made by Movianto UK encompasses this area of business and the company has more than doubled their capacity for the storage of narcotics in Bedford and can safely ensure the safe transportation of the drugs throughout mainland UK.

To further round off the service offering, the healthcare logistic specialists are now providing new manufacturing services which include the kitting, relabelling and repackaging of medication. Existing clients find these services particularly useful as it saves them time and resources, for example when adapting their products to specific market requirements.

Managing Director of Movianto UK, Russell Atkinson commented "Our continued investment in the UK demonstrates our commitment to the market and our understanding of the future needs of the industry."

About Movianto UK

Movianto UK is a subsidiary of the Europe-wide Movianto Group, a leading logistics and distribution service provider for the pharmaceutical and healthcare industry. With a pallett storage capacity of over 50,000 spaces as well as eight strategically located warehouses and depots throughout the country, Movianto UK is able to deliver to every UK hospital and pharmaceutical wholesaler on a daily basis with its own fleet. The company also delivers cold chain and ambient medicines and healthcare products to supermarkets, pharmacies, GPs, nursing homes and direct to patients' homes on a next day basis.

The Movianto Group operates in 13 European countries offering a total storage capacity of 225,000 pallett spaces. Movianto is a business unit of Celesio AG. More information on http://www.movianto.com.

Contact
Richard Shore, Tel. +44(0)1234-248678 / Fax: +44(0)1234-248704
Movianto UK, 1 Progress Park, Bedford, MK42 9XE, United Kingdom
Email: [email protected]
Internet: http://www.movianto.com

Vineeta Manglani, Tel. + 49-711/947-67-0, Fax + 49-711/9-47-67-87
Sympra GmbH (GPRA), Stafflenbergstrasse 32, 70184 Stuttgart, Germany
E-Mail: [email protected]
Internet:http://www.sympra.de

 

Distributed by PR Newswire on behalf of Movianto GmbH


--------------------------------------------------------------------------------

Contact details for all releases are only available to the media via PR Newswire for Journalists.


--------------------------------------------------------------------------------
PR Newswire Europe Ltd.

209 - 215 Blackfriars Road, London, SE1 8NL
Tel :   +44 (0)20 7490 8111
Fax :   +44 (0)20 7490 1255
E-mail :   [email protected]
 

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.